目的：本研究旨在探讨地西他滨联合改良的CAG方案对复发、难治急性髓系白血病（acute myeloid leukemia,AM L）的治疗效果及不良反应。方法：回顾性分析了我科2013年1月至7月收治的10例复发、难治AM L,观察其临床特征、治疗效果及不良反应。10例患者中,男性7例,女性3例,男女比例7∶3,中位年龄45（17-61）岁。结果：10例患者经过地西他滨联合改良CAG方案治疗后7例完全缓解,1例部分缓解,2例未缓解,总缓解率80%（8/10）。白细胞数恢复中位时间18.5（5-28）d,血小板水平恢复中位时间19（12-29）d。治疗的主要副作用为骨髓抑制,10例治疗中未出现新发肺部感染等严重并发症,1例由于化疗原发肺部感染加重死亡。结论：地西他滨结合改良CAG治疗复发、难治AML具有高缓解率,低副反应的特点,值得在临床上进一步性研究。
Objective： This study was to investigate the therapeutic effectiveness and side effect of decitabine combined with modified CAG regimen for relapse or refractory patients with acute myeloid leukemia. Methods：Ten patients suffered from relapsed or refractory acute myeloid leukemia from January 2013 to July 2013 were analyzed retrospectively, and the clinical characteristics, therapeutic effectiveness, side effect were observed. Among 10 patients 7 patients were males and 3 patients were females, the ratio of male to female was 7： 3, median age was 45 （ 17 - 61 ） years. Results： After treatment by using decitabine combined with modified CAG regimen, 7 patients achived complete remission, 1 patient achived partial remission, 2 patient did not achieve remission, the overall remission rate was 80% （8/10）, the median time of white blood cell count recovery was 18.5 （5 -28）days, median time of platelet level recovery was 19（ 12 -29 ） days. The main side effects of treatment were myelosuppression. There was no new lung infection in all cases, one case died of exacerbation of primary lung infection after therapy. Conelution： The treatment of decitabine combined with modified CAG regimen for relapsed and refractory AML shows high response rate, low side effects, so it worthy to further clinical study.
Journal of Experimental Hematology